VP6-2021: IMpassion050: A phase III study of neoadjuvant atezolizumab + pertuzumab + trastuzumab + chemotherapy (neoadj A + PH + CT) in high-risk, HER2-positive early breast cancer (EBC)

Annals of Oncology ◽

10.1016/j.annonc.2021.05.800 ◽

2021 ◽

Author(s):

J. Huober ◽

C.H. Barrios ◽

N. Niikura ◽

M. Jarzab ◽

Y-C. Chang ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Early Breast Cancer ◽

Phase Iii ◽

Her2 Positive ◽

Phase Iii Study

Download Full-text

42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P after anthracyclines (AC) for high-risk HER2-positive early breast cancer (EBC)

Annals of Oncology ◽

10.1016/j.annonc.2021.03.056 ◽

2021 ◽

Vol 32 ◽

pp. S37-S38

Author(s):

O. Metzger ◽

C. Lambertini ◽

I.E. Krop ◽

G. Lewis Phillips ◽

C.M. Perou ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Early Breast Cancer ◽

Phase Iii ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Adjuvant Trastuzumab ◽

Biomarker Analysis ◽

Phase Iii Study

Download Full-text

A phase III study comparing SB3 (a proposed trastuzumab biosimilar) and trastuzumab reference product in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment: Final safety, immunogenicity and survival results

European Journal of Cancer ◽

10.1016/j.ejca.2018.01.072 ◽

2018 ◽

Vol 93 ◽

pp. 19-27 ◽

Author(s):

X. Pivot ◽

I. Bondarenko ◽

Z. Nowecki ◽

M. Dvorkin ◽

E. Trishkina ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Adjuvant Treatment ◽

Reference Product ◽

Phase Iii ◽

Her2 Positive ◽

Phase Iii Study

Download Full-text

Abstract S4-2: First Efficacy Results of a Randomized, Open-Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without Capecitabine, in High-Risk Early Breast Cancer

10.1158/0008-5472.sabcs10-s4-2 ◽

2010 ◽

Author(s):

J O'Shaughnessy ◽

D Paul ◽

C Stokoe ◽

J Pippen Jr ◽

JL Blum ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Early Breast Cancer ◽

Phase Iii ◽

Open Label Phase ◽

Phase Iii Study

Download Full-text

Adjuvant Subcutaneous Trastuzumab for HER2‐Positive Early Breast Cancer: Subgroup Analyses of Safety and Active Medical Conditions by Body Weight in the SafeHer Phase III Study

The Oncologist ◽

10.1634/theoncologist.2018-0065 ◽

2018 ◽

Vol 23 (10) ◽

pp. 1137-1143 ◽

Author(s):

Kyung Hae Jung ◽

Beyhan Ataseven ◽

Mark Verrill ◽

Xavier Pivot ◽

Michelino De Laurentiis ◽

...

Keyword(s):

Breast Cancer ◽

Body Weight ◽

Early Breast Cancer ◽

Phase Iii ◽

Medical Conditions ◽

Her2 Positive ◽

Subgroup Analyses ◽

Breast Cancer Subgroup ◽

Phase Iii Study

Download Full-text

Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC) → docetaxel (T) with or without capecitabine (X) in high-risk early breast cancer: Exploratory Ki-67 analyses.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.500 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 500-500 ◽

Author(s):

J. E. Pippen ◽

D. Paul ◽

C. T. Stokoe ◽

J. L. Blum ◽

L. Krekow ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Early Breast Cancer ◽

Phase Iii ◽

Ki 67 ◽

Phase Iii Study

Download Full-text

Sequential vs concurrent epirubicin and docetaxel as adjuvant chemotherapy for high-risk, node-negative, early breast cancer: an interim analysis of a randomised phase III study from the Hellenic Oncology Research Group

British Journal of Cancer ◽

10.1038/bjc.2017.158 ◽

2017 ◽

Vol 117 (2) ◽

pp. 164-170 ◽

Author(s):

Dimitrios Mavroudis ◽

Emmanouil Saloustros ◽

Ioannis Boukovinas ◽

Pavlos Papakotoulas ◽

Stylianos Kakolyris ◽

...

Keyword(s):

Breast Cancer ◽

High Risk ◽

Adjuvant Chemotherapy ◽

Early Breast Cancer ◽

Research Group ◽

Interim Analysis ◽

Phase Iii ◽

Node Negative ◽

Oncology Research ◽

Phase Iii Study

Download Full-text

P272 Randomized, phase III study of adjuvant doxorubicin plus cyclophosphamide (AC), followed by docetaxel (T) with or without capecitabine (X), in high-risk early breast cancer (EBC): efficacy results

10.1016/s0960-9776(11)70214-4 ◽

2011 ◽

Vol 20 ◽

pp. S65 ◽

Author(s):

J. O'Shaughnessy ◽

C. Brownstein ◽

S. Hörsch ◽

N. Scotto

Keyword(s):

Breast Cancer ◽

High Risk ◽

Early Breast Cancer ◽

Phase Iii ◽

Phase Iii Study

Download Full-text

Double-blind, randomized phase III study to compare the efficacy and safety of trastuzumab and its biosimilar candidate CT-P6 in HER2 positive early breast cancer (EBC)

Annals of Oncology ◽

10.1093/annonc/mdx362.003 ◽

2017 ◽

Vol 28 ◽

pp. v44-v45 ◽

Author(s):

F.J. Esteva ◽

Y. Baranau ◽

V. Baryash ◽

A. Manikhas ◽

V. Moiseyenko ◽

...

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Phase Iii ◽

Efficacy And Safety ◽

Her2 Positive ◽

Double Blind ◽

Phase Iii Study

Download Full-text

1956 Safety and tolerability of subcutaneous trastuzumab for HER2-positive early breast cancer in patients with lower body weight and in Asian patients: SafeHer Phase III study subgroup analyses

European Journal of Cancer ◽

10.1016/s0959-8049(16)30904-2 ◽

2015 ◽

Vol 51 ◽

pp. S318

Author(s):

K.H. Jung ◽

B. Ataseven ◽

M. Verrill ◽

M. De Laurentiis ◽

H.A. Azim ◽

...

Keyword(s):

Breast Cancer ◽

Body Weight ◽

Early Breast Cancer ◽

Phase Iii ◽

Her2 Positive ◽

Asian Patients ◽

Lower Body Weight ◽

Subgroup Analyses ◽

Phase Iii Study

Download Full-text

PCN344 ADDITION OF PERTUZUMAB TO TRASTUZUMAB-BASED ADJUVANT THERAPY IN HIGH-RISK HER2-POSITIVE EARLY BREAST CANCER: A GRADE-BASED ANALYSIS FROM THE PHASE III APHINITY TRIAL

Value in Health ◽

10.1016/j.jval.2019.09.539 ◽

2019 ◽

Vol 22 ◽

pp. S503

Author(s):

F. Piccolo ◽

G. Pappagallo ◽

A. Zambelli ◽

A. Caputo

Keyword(s):

Breast Cancer ◽

High Risk ◽

Adjuvant Therapy ◽

Early Breast Cancer ◽

Phase Iii ◽

Download Full-text